Kidney drug study aims to understand dosing, not cure

NCT ID NCT07348237

First seen Jan 17, 2026 · Last updated May 08, 2026 · Updated 11 times

Summary

This study looks at how the drug MK-2828 behaves in the bodies of people with different levels of kidney function, including those on dialysis. About 24 adults will receive one or two doses, and researchers will track the drug levels in their blood over time. The goal is to see if kidney disease changes how the drug is processed, which can help guide future dosing. This is not a treatment study—participants receive the drug only for measurement purposes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Floridian Clinical Research ( Site 0001)

    RECRUITING

    Miami Lakes, Florida, 33016, United States

    Contact Phone: •••-•••-••••

  • Orlando Clinical Research Center ( Site 0002)

    RECRUITING

    Orlando, Florida, 32809, United States

    Contact Phone: •••-•••-••••

  • Panax Clinical Research ( Site 0003)

    RECRUITING

    Miami Lakes, Florida, 33014, United States

    Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.